Press release
Obesity Therapeutics Market Set to Record US$ 63.75 Billion by 2033., Growth by surge - Eli Lilly, Kissei Pharmaceutical, Daiichi Sankyo, Novo Nordisk, Takeda Pharmaceutical Company Limited, and KVK Tech Inc
Obesity Therapeutics Market Size 2026
The GLP-1 receptor agonists segment led the obesity therapeutics market in 2024, accounting for a dominant 45.3% share.
Ready to scale in the Obesity Therapeutics Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/competitive-landscape-of-the-global-obesity-therapeutics-market?kb
United States: Recent Industry Developments (May 2026 to Jan 2026)
✅ March 2026: Eli Lilly and Company expanded late-stage clinical trials of next-generation GLP-1/GIP dual agonists targeting improved weight loss efficacy and cardiometabolic outcomes.
✅ February 2026: Novo Nordisk strengthened U.S. manufacturing capacity for semaglutide-based therapies to meet rising demand in obesity and diabetes treatment markets.
✅ January 2026: Amgen advanced Phase 3 development of novel obesity biologics focusing on long-acting incretin receptor agonists with improved tolerability profiles.
✅ December 2025: Pfizer Inc. progressed its oral obesity drug pipeline, emphasizing small-molecule GLP-1 receptor modulators aimed at non-injectable treatment alternatives.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/competitive-landscape-of-the-global-obesity-therapeutics-market?kb
List of Key Players 2026:
Novo Nordisk, Eli Lilly, VIVUS LLC, Currax Pharmaceuticals LLC, GSK plc, Roche Laboratories Inc, AstraZeneca, Rhythm Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, and KVK Tech, Inc
Growth Forecast Projected 2026:
The Global Obesity Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Key Developments 2025-2026:
✅ May 2026: Pharmaceutical companies advanced next-generation multi-target anti-obesity therapies, combining GLP-1, GIP, and amylin pathways to improve long-term weight reduction and metabolic control outcomes.
✅ March 2026: Clinical trials expanded for oral obesity therapeutics, with strong focus on improving patient adherence compared to injectable GLP-1 receptor agonists.
✅ January 2026: Leading drug developers scaled production of GLP-1-based therapies to address sustained global shortages driven by surging demand for obesity and diabetes management treatments.
✅ November 2025: Regulatory agencies accelerated review pathways for innovative obesity drugs showing dual benefits in weight loss and cardiovascular risk reduction.
✅ October 2025: Pharmaceutical pipelines saw increased investment in combination therapies targeting appetite regulation, insulin sensitivity, and energy metabolism for improved clinical efficacy.
How Our Market Research Process Works:
The global Obesity Therapeutics Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Obesity Therapeutics ecosystem.
Recent Mergers & Acquisitions (M & A) 2025-2026:
• Jan 2026: Eli Lilly expanded obesity pipeline via acquisition of Ventyx Biosciences, strengthening metabolic inflammation and weight-loss drug development portfolio
• Jan 2026: Eli Lilly entered AI-driven obesity drug development collaboration with Nimbus Therapeutics, including up to ~$1.3B milestone-linked deal structure for oral obesity therapies
• Mar 2026: Biogen acquired Apellis Pharmaceuticals for $5.6B, expanding into complement-mediated diseases with metabolic and obesity-adjacent implications in downstream inflammation pathways
• Apr 2026: Gilead Sciences acquired Tubulis for up to ~$5.0B, strengthening oncology pipeline with indirect metabolic and obesity-linked disease burden applications in ADC platforms
Request Strategic Market Customization: https://datamintelligence.com/customize/competitive-landscape-of-the-global-obesity-therapeutics-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company enhanced metabolic disease research programs focusing on next-generation obesity and NASH (MASH) combination therapies.
✅ February 2026: Astellas Pharma initiated strategic collaborations to develop precision medicine approaches targeting obesity-linked hormonal pathways.
✅ January 2026: Daiichi Sankyo expanded early-stage clinical studies evaluating novel appetite-regulating compounds for obesity and metabolic syndrome.
✅ December 2025: Kissei Pharmaceutical advanced metabolic disorder pipeline programs with emphasis on gut-hormone based obesity therapeutics and patient-specific treatment models.
Major Focused Key Segmentations 2026:
By Drug Class: GLP-1 Receptor Agonists, Lipase Inhibitors, Melanocortin-4 Receptor Agonists, Appetite Suppressants and Others
By Route of Administration: Parenteral, Oral and Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regional Growth Analysis for Market:
⇥ North America: 48.5% - Dominates the global obesity therapeutics market due to high obesity prevalence, strong adoption of GLP-1 therapies, and advanced healthcare infrastructure.
⇥ Europe: 20% - Driven by increasing obesity awareness, reimbursement support, and growing uptake of pharmacological weight management therapies.
⇥ Asia-Pacific: 18.5% - Fastest-growing region supported by rising obesity rates, expanding healthcare access, and increasing adoption of modern therapeutics.
⇥ Middle East & Africa: 6% - Gradual growth driven by lifestyle-related obesity cases and improving healthcare investments.
⇥ South America: 7% - Expanding market supported by rising chronic disease burden and increasing access to obesity treatment options.
1. Latest Drug Developments (Recent & Emerging)
The obesity drug landscape is rapidly evolving beyond traditional GLP-1 monotherapy into multi-hormone and next-generation metabolic therapies.
🔹 GLP-1 / Incretin-Based Upgrades
✦ Oral GLP-1 therapies (e.g., oral semaglutide, oral Wegovy expansion) improving patient convenience and adherence
Shift from injectable to oral once-daily or oral weekly formulations
✦ Enhanced formulations targeting better weight loss maintenance and cardiovascular benefit
🔹 Dual Agonists (GLP-1 + GIP / GLP-1 + Amylin)
✦ CagriSema (Novo Nordisk) - GLP-1 + amylin combo showing 20%+ weight loss in trials
✦ Amycretin (Novo Nordisk) - GLP-1 + amylin dual agonist; up to 22-25% weight loss in early trials
✦ Survodutide (Boehringer Ingelheim) - GLP-1 + glucagon dual agonist for metabolic and liver fat reduction
🔹 Triple Agonists (Next-Gen Breakthroughs)
Retatrutide (Eli Lilly) - GLP-1 + GIP + glucagon
Up to 24-29% weight loss in trials
Considered the most potent obesity drug candidate so far
🔹 Next Wave Innovations
✦ Monthly injectable therapies (long-acting peptides)
✦ Muscle-sparing obesity drugs (targeting fat loss preservation)
Combination metabolic therapies targeting appetite + energy expenditure + fat oxidation
Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=competitive-landscape-of-the-global-obesity-therapeutics-market?kb
2. Obesity Drug Pipeline (By Phase)
Phase 3 / Late-Stage Pipeline (Closest to Market)
✦ Retatrutide (Eli Lilly) - Triple agonist (GLP-1/GIP/Glucagon)
✦ CagriSema (Novo Nordisk) - GLP-1 + Amylin
✦ Amycretin (Novo Nordisk) - GLP-1 + Amylin dual
✦ MariTide (Amgen) - GLP-1/GIP pathway modulation
✦ Survodutide (Boehringer Ingelheim) - GLP-1 + Glucagon dual
✦ Oral Semaglutide high-dose versions (Novo Nordisk)
Phase 2 Pipeline (Mid-stage Clinical Development)
✦ Viking VK2735 - Dual GLP-1/GIP agonist
✦ Roche CT-388 - Dual GLP-1/GIP agonist
✦ Altimmune Pemvidutide - GLP-1 + Glucagon dual
✦ Pfizer Metsera program (PF-0683944 class) - monthly GLP-1 injectables
✦ UBT251 (China/Novo collaboration) - triple agonist early data (19-20% weight loss)
Early Pipeline / Preclinical & Phase 1
✦ Quadruple agonists (experimental next-gen molecules) targeting GLP-1 + GIP + glucagon + additional metabolic receptors
✦ Non-incretin obesity drugs (fat oxidation, muscle preservation, CNS appetite control)
Gene-based and peptide hybrid therapies
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Obesity Therapeutics Market Set to Record US$ 63.75 Billion by 2033., Growth by surge - Eli Lilly, Kissei Pharmaceutical, Daiichi Sankyo, Novo Nordisk, Takeda Pharmaceutical Company Limited, and KVK Tech Inc here
News-ID: 4506962 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Chronic Wound Care Market to Reach USD 26.76 Billion by 2033 at 6.8% CAGR; North …
The global chronic wound care market was valued at USD 15.16 billion in 2025 and is projected to reach USD 26.76 billion by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by the increasing prevalence of diabetes, obesity, vascular diseases, and pressure ulcers, along with the rising geriatric population worldwide. Chronic wounds such as diabetic foot…
Why the Carbon Nanotubes Market Is Expanding Faster Than Advanced Materials Expe …
The global Carbon Nanotubes market is witnessing strong growth as industries increasingly adopt lightweight, high-strength, and electrically conductive materials to enhance product performance and energy efficiency. The growing use of carbon nanotubes (CNTs) in electronics, electric vehicles, energy storage systems, aerospace components, and advanced composites is accelerating market expansion worldwide.
Carbon nanotubes are gaining significant attention due to their exceptional mechanical strength, thermal conductivity, and electrical properties, making them critical materials…
Why the Sodium-Ion Battery Market Is Advancing Faster Than the Energy Industry E …
The global Sodium-Ion Battery market is witnessing rapid growth as energy storage manufacturers, automotive companies, and governments search for affordable and sustainable alternatives to conventional lithium-ion batteries. Rising concerns over lithium supply constraints, increasing raw material costs, and the growing demand for large-scale energy storage solutions are accelerating investment in sodium-ion battery technologies worldwide.
Sodium-ion batteries are emerging as a promising next-generation energy storage solution due to the abundant availability of…
Nanosatellite and Microsatellite Market Set for Explosive Growth to US$ 19.64 Bi …
DataM Intelligence has released a new research report titled "Nanosatellite and Microsatellite Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in…
More Releases for Mar
George Chung's Longstanding Leadership in Mar Vista Real Estate
Byline: Magnifyde PR
Image: https://www.globalnewslines.com/uploads/2026/04/06922deb1840587a4107af708a1f6ecf.jpg
In the Los Angeles neighborhood of Mar Vista, real estate expertise often comes down to familiarity with the community itself. Few professionals embody that local focus more clearly than George Chung, President Broker of George Chung Realtors. Over the course of his career, he has built a reputation centered on a single neighborhood, developing an unusually deep knowledge of the housing market in the 90066 area.
While many…
Consumer Adoption Of Smartphones And Tablets Fuels The Mobile Augmented Reality …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Mobile Augmented Reality (MAR) Market Size Growth Forecast: What to Expect by 2025?
In recent years, the market size of mobile augmented reality (MAR) has been expanding dramatically. The market is projected to increase from $27.57 billion in 2024 to $37.19 billion in 2025, with a compound annual growth…
1 New Article from Happy Smoking - MAR 2025
Happy Smoking is your definitive guide to smoking culture, providing expert reviews, comprehensive guides, and a platform for aficionados to connect and share their passion. We offer responsible, accurate information on enjoying cigars, pipes, and hookahs
.
Austin, TX - MAR 2025: Happy Smoking, a leader in smoking guides and expert reviews, is thrilled to announce the publishing of 1 new article on our platform. This month's update includes a diverse range…
Bungalows Del Mar Office by Harbor Associates in Del Mar, California Defies Nati …
Image: https://www.abnewswire.com/upload/2025/01/5bf83fc4238a3b3089be31e9b2ba64df.jpg
Seal Beach, CA - January 17, 2025 - Harbor Associates, LLC ("Harbor"), a value add and opportunistic buyer and owner in the office market, completed the lease up of the Bungalows Del Mar Office (https://www.thebungalowsdelmar.com/) despite the pandemic and work from home trends and now the recession that has slowed traditional office leasing. This Del Mar office space created by Harbor has been so successful that a rare…
Mobile Augmented Reality (MAR) Market 2021 | Detailed Report
The Mobile Augmented Reality (MAR) research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information about the…
Casa Del Mar - Bronx's Exquisite Bar and Restaurant
Bronx, New York City, Release: March 19, 2020
Seafood Dining at Its Best
Are you on a seafood diet?
If you are on a seafood diet, then what's better than sitting at Casa Del Mar, get hooked on seafood at a beautiful restaurant located in the heart of the Bronx that features the most exquisite seafood cuisine of all times.
Established on, the restaurant is an ideal seafood destination for all the gastronomes and…
